
Assembly Biosciences (ASMB) Stock Forecast & Price Target
Assembly Biosciences (ASMB) Analyst Ratings
Bulls say
Assembly Biosciences is in a strong financial position with positive developments for their promising pipeline, including potential partnerships for their HSV treatment and a licensing agreement with Gilead for two drugs. These developments have increased the probability of success for their antiviral pipeline and have de-risked their financials. Their commercial strategy for HSV aims to provide a more effective and convenient option for patients, which could lead to higher revenues and potential partnerships for additional funding. Overall, the company's compelling pipeline and financial stability make it an attractive investment opportunity in the biotech sector.
Bears say
Assembly Biosciences is highly reliant on partnerships and collaboration with companies like Gilead, which increases the company's risk and dependence on the success of these partnerships. Furthermore, there are significant risks associated with the company's clinical development process, as well as potential delays in manufacturing and regulatory approval. These factors, along with the small potential market for their treatments, lead to a negative outlook on the stock.
This aggregate rating is based on analysts' research of Assembly Biosciences and is not a guaranteed prediction by Public.com or investment advice.
Assembly Biosciences (ASMB) Analyst Forecast & Price Prediction
Start investing in Assembly Biosciences (ASMB)
Order type
Buy in
Order amount
Est. shares
0 shares